A retrospective study of 34ï¿½patients with unicentric and multicentric Castleman's disease: Experience from a single institution

Jiang, Jinpeng; Shen, Xiaofei; Du, Junfeng; Guan, Wenxian

doi:10.3892/ol.2017.7625

Cited by 14 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 summarizes published data and data from the ongoing ACCEL-ERATE natural history registry 32 from the CDCN and University of Pennsylvania. 12,19,[33][34][35][36][37][38][39][40][41][42][43][44][45] The consensus focused on 2 main topics: treatment of resectable UCD and treatment of unresectable UCD. Levels of evidence were modeled after National Comprehensive Cancer Network guidelines.…”

Section: Introductionmentioning

confidence: 99%

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease

et al. 2020

View full text Add to dashboard Cite

Castleman disease (CD) includes a group of rare and heterogeneous disorders with characteristic lymph node histopathological abnormalities. CD can occur in a single lymph node station, which is referred to as unicentric CD (UCD). CD can also involve multicentric lymphadenopathy and inflammatory symptoms (multicentric CD [MCD]). MCD includes human herpesvirus-8 (HHV-8)–associated MCD, POEMS-associated MCD, and HHV-8−/idiopathic MCD (iMCD). The first-ever diagnostic and treatment guidelines were recently developed for iMCD by an international expert consortium convened by the Castleman Disease Collaborative Network (CDCN). The focus of this report is to establish similar guidelines for the management of UCD. To this purpose, an international working group of 42 experts from 10 countries was convened to establish consensus recommendations based on review of treatment in published cases of UCD, the CDCN ACCELERATE registry, and expert opinion. Complete surgical resection is often curative and is therefore the preferred first-line therapy, if possible. The management of unresectable UCD is more challenging. Existing evidence supports that asymptomatic unresectable UCD may be observed. The anti–interleukin-6 monoclonal antibody siltuximab should be considered for unresectable UCD patients with an inflammatory syndrome. Unresectable UCD that is symptomatic as a result of compression of vital neighboring structures may be rendered amenable to resection by medical therapy (eg, rituximab, steroids), radiotherapy, or embolization. Further research is needed in UCD patients with persisting constitutional symptoms despite complete excision and normal laboratory markers. We hope that these guidelines will improve outcomes in UCD and help treating physicians decide the best therapeutic approach for their patients.

show abstract

Section: Introductionmentioning

confidence: 99%

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…We present a case of Castleman disease in a patient with Klinefelter syndrome, imitating paraganglioma as per the clinical, radiological and laboratory findings. resemble various diseases during the onset (4). This paper reports an unusual presentation of retroperitoneal CD, mimicking paraganglioma in a patient with Klinefelter syndrome.…”

Section: Introductionmentioning

confidence: 84%

Retroperitoneal Castleman Disease Mimicking Paraganglioma in a Patient with Klinefelter Syndrome: A Case Report

Hepşen¹,

Özbek²,

Sencar³

et al. 2019

Turk J Endocrinol Metab

View full text Add to dashboard Cite

“…A small number of patients develop a terrible syndrome, including multiple neuropathies, organ enlargement, endocrine disorders, monoclonal gamma globulin disease, and skin changes. The median survival time is approximately 14 months 3 , 4 .…”

Section: Discussionmentioning

confidence: 99%

A Case of Successful Allogeneic Hematopoietic Stem Cell Transplantation for HHV8-Positive Castleman’s Disease with a Review of the Literature

et al. 2020

View full text Add to dashboard Cite

Objective: To investigate the long-term clinical efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with human herpes virus 8 (HHV8)-positive multicentric Castleman’s disease (MCD). Methods: A 17-year-old female patient was admitted to Henan Provincial People’s Hospital with the complaint of febrile for half a month, headache, and enlarged superficial lymph nodes on October 5, 2010. HHV8-positive mixed cellular Castleman’s disease was found by pathological diagnosis of lymph nodes biopsy. After the administration of CHOP and Hyper-CVAD-B, the patient was still febrile, we administrated the followed COAP, two courses of VAD(Vincristine, Adriamycin, Dexamethasone), the patient received CR. Six months after CR, the patient relapsed, we administrated VAD and two courses of bortezomide+dexamethasone chemotherapy, and then the patient received PR. After that, the patient underwent allo-HSCT from his human leukocyte antigen (HLA)-matched unrelated donor after conditioning with Bu/Cy+Etoposide+Smoustin.graft-vs-host disease (GVHD) prophylaxis, which consisted of ATG (7.5 mg/kg, qd, ivdrip) from d-5 to d-2, cyclosporine (3 mg/kg/d, qd, ivdrip, for 24 h) started from day-1, MMF(0.5 g, tid, po.) started from day+1 to +28, and MTX (15 mg per time, ivdrip, d+1,+4,+7,+11). She received 3.5×106/L CD34+cells and 8.1×108/LMNC. Results: Granulocyte engraftment occurred on day+12, platelet engrafted on day+14. Bone marrow biopsy showed normalization of trilineage hematopoiesis on day+33, chimerism: 97.6%. The transplantation was successful and followed up for 7 years with CR. Conclusion: Allo-HSCT might cure patients with refractory/relapsed HHV8+ MCD.

show abstract

A retrospective study of 34ï¿½patients with unicentric and multicentric Castleman's disease: Experience from a single institution

Abstract: Abstract. The aim of the present study was to share the

Cited by 14 publications

References 28 publications

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease

Retroperitoneal Castleman Disease Mimicking Paraganglioma in a Patient with Klinefelter Syndrome: A Case Report

A Case of Successful Allogeneic Hematopoietic Stem Cell Transplantation for HHV8-Positive Castleman’s Disease with a Review of the Literature

Contact Info

Product

Resources

About